Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net loss	$ (7,148,459)	$ (6,779,018)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	20,783	734,395
Asset impairment loss	402,746
Depreciation		30,758
Inducement expense		2,567,044
Change in fair value of derivative instrument-warrants	4,102,408	(4,439,752)
Change in fair value of contingent consideration		(2,020,000)
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	(22,693)	(3,967,907)
Right of use asset		62,145
Operating lease liability		(54,930)
Prepaid expenses and other assets	152,433	(678,232)
Net cash used in operating activities	(2,492,782)	(14,545,497)
Cash flows from investing activities:
Investment in license agreement	(132,117)
Net cash used in investing activities	(132,117)
Cash flows from financing activities:
Proceeds from the issuance of common stock and warrants, net	9,000,000	1,849,707
Equity issuance costs	(802,597)
Payments on notes payable	(3,054,517)
Net cash provided by financing activities	5,142,886	1,849,707
Effect of exchange rates on cash		24,957
Net increase (decrease) in cash	2,517,987	(12,670,833)
Cash at beginning of period	406,408	14,785,880
Cash at end of period	2,924,395	2,115,047
Supplementary disclosure of non-cash investing and financing activities:
Issuance of Note Payable for payment of prepaid expense	526,178
Inducement expense for issuance of Series B-1 and B-2 warrants		2,821,399
Cashless Exercise of 2025 Series B Warrants	10,430,732
Issuance of common stock in connection with license agreement	$ 270,629